Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single ...

Pfizer has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla, delaying generic competition for its blockbuster ATTR-CM drug Vyndamax until 2031. The move preserves ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

Bristol Myers Squibb reported a first-quarter profit that beat Wall Street expectations on Thursday, helped by ...

Investors who seek out dividend stocks pay close attention to a company's dividend yield, and high-yield players -- as long ...

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...

April 29 () - Pfizer said on Wednesday its drug Elrexfio met the main goal in ‌a late-stage trial that tested the blood ...

Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t ...

On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on ...